Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway - Summary - MDSpire

Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

  • By

  • Biao Zheng

  • Guojun Yao

  • Yuli Pang

  • Jielong Luo

  • Zhiyong Yang

  • Fengmin Xiu

  • Chaohui Zhen

  • Rui Liang

  • June 9, 2026

  • 0 min

Share

Objective:

To explore whether Tetrandrine (TET) can enhance the anti-PD-1 therapeutic effect in hepatocellular carcinoma (HCC) by activating the STING/TBK1/IRF3 signaling pathway.

Key Findings:
  • TET significantly inhibited HCC growth and induced apoptosis.
  • TET promoted CD8+ T cell activation, proliferation, and cytotoxicity.
  • TET activated the STING/TBK1/IRF3 signaling pathway.
  • TET and anti-PD-1 showed a significant synergistic anti-tumor effect.
  • No obvious toxic reactions were observed.
Interpretation:

Limitations:
  • The study primarily focuses on mouse models, which may not fully replicate human responses.
  • The long-term effects and safety of TET in combination with anti-PD-1 therapy require further investigation.
Conclusion:

Original Source(s)

Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway

  • by Biao Zheng, Guojun Yao, Yuli Pang, Jielong Luo, Zhiyong Yang, Fengmin Xiu, Chaohui Zhen, Rui Liang

  • June 9, 2026

Related Content

Subcutaneous patient-controlled analgesia with hydromorphone for the treatment of refractory cancer pain in older hospitalized patients: a retrospective real-world study

Correction: Accessibility to molecular studies in gliomas: a challenge for precision medicine in low-resource countries

D-VRD induction and autologous transplant in patients ≥70 years